Karyopharm Therapeutics Q2 revenue falls 11%

Karyopharm Therapeutics

11/08/2025 12:40

Overview

Karyopharm Q2 2025 total revenue declines to $37.9 mln from $42.8 mln in 2024

U.S. XPOVIO net product revenue rises 6% yr/yr to $29.7 mln

Company reaffirms 2025 total revenue guidance, updates XPOVIO revenue forecast

Exploring financing and strategic alternatives to extend cash runway

Outlook

Karyopharm reaffirms 2025 total revenue guidance of $140 mln to $155 mln

Company updates 2025 U.S. XPOVIO revenue guidance to $110 mln to $120 mln

Karyopharm exploring financing and strategic alternatives to extend cash runway

Top-line results for SENTRY trial expected in March 2026

Result Drivers

XPOVIO SALES - U.S. XPOVIO net product revenue rose 6% yr/yr to $29.7 mln, driven by consistent demand and community setting

ROYALTY REVENUE - Expanded global patient access for selinexor increased royalty revenue by 28% yr/yr to $1.6 mln

LICENSE REVENUE DECLINE - Total revenue impacted by decrease in license revenue due to non-recurring items in prior year

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$29.68 mln
Q2 Net Income
-$37.25 mln
Q2 Operating Expenses
$62.32 mln
Q2 Operating Income
-$24.39 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $15.00, about 73.7% above its August 8 closing price of $3.94

Press Release: ID:nPn9Zcq2Ya

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)